- Investing Ideas
- U.S. Pharmaceuticals & Biotech Buy the Dip
U.S. Pharmaceuticals & Biotech Buy the Dip
Results
6
Companies which have seen a dip in the last 7 days after continued gains and are looking undervalued based on Snowflake checks.
6 companies
Replimune Group
Market Cap: US$814.5m
A clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom.
REPL
US$8.63
7D
-17.9%
1Y
172.2%
Zentalis Pharmaceuticals
Market Cap: US$308.2m
A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
ZNTL
US$4.51
7D
-10.0%
1Y
213.2%
MacroGenics
Market Cap: US$254.3m
A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
MGNX
US$4.00
7D
-11.9%
1Y
153.2%
Kazia Therapeutics
Market Cap: US$140.1m
Operates as an oncology-focused biotechnology company in Israel.
KZIA
US$12.21
7D
-9.9%
1Y
42.5%
PepGen
Market Cap: US$133.5m
A clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
PEPG
US$1.90
7D
-13.6%
1Y
32.9%
Numinus Wellness
Market Cap: US$12.8m
Provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States.
NUMI.F
US$0.044
7D
-9.1%
1Y
49.5%